Location Fort Lauderdale, Florida, United States Regions Greater Miami Area, East Coast, Southern US Gender Male
Website richardpestell.com/ Facebook View on Facebook LinkedIn View on LinkedIn X (Twitter) View on X
Richard Pestell began his medical journey at the University of Western Australia, where he graduated at the top of his class and earned an M.B., B.S. His early clinical formation included a physician-in-training role at the Royal Perth Hospital and St Vincent's Hospital, Sydney. These years provided extensive exposure to Internal Medicine and
residency, including oncology, endocrinology, hematology, cardiology, and transplant medicine.
He developed a strong interest in cancer biology and pursued advanced research, culminating in a Ph.D. from the University of Melbourne at the Howard Florey Institute. His doctoral focus was on the regulation of gene transcription by oncogenes. National scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award, supported his academic progress. These achievements led him to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow.
Richard continued his academic pathway at Northwestern University and later at the Albert Einstein College of Medicine. He became a Professor, Chair of the Division of Endocrine-Dependent Tumor Biology, and Co-Director of major cancer research programs. He also held positions at multiple hospitals in New York, which helped him remain involved in patient care and medical education while advancing research priorities.
Richard Pestell’s research contributed to the knowledge base supporting cancer therapeutics. His research on cyclin D1 was cited in the seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. His work on CCR5 also provided the scientific framework for current oncology clinical trials with CCR5 inhibitors. Across his publication record, he has published over 700 works, received more than 110,000 citations, an h-index of 162, and given extensive invited lectures around the world.
In 2002, Richard became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University. He also served as Chair of the Department of Oncology and Associate Vice President at Georgetown University Medical Center. In these roles, he was responsible for research, clinical operations, and faculty development, and he was involved in institutional restructuring and growth. He supported community partnerships, strengthened research programs, and expanded clinical services across Georgetown and MedStar systems.
Richard took on additional leadership responsibilities in 2005 as the Director of the Sidney Kimmel Cancer Center, Chair of the Department of Cancer Biology, and head of the Oncology Service Line at Thomas Jefferson University. He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of> $350 m and led initiatives in clinical care, research infrastructure, regional expansion, and team building. During his tenure, the cancer center rose from 64th to 17th.
Richard Pestell also held leadership roles in academia outside of the US and contributed to education and outreach initiatives. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. He also served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions.
He has served with prominent scientific bodies, including the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His honors include the RD Wright Medallion, the Eric Susman Prize in Medicine, and his appointment as an Officer of the Order of Australia in 2019. He is also the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. He has raised nearly 50 million dollars from investors and more than 80 million dollars as a principal investigator on NIH research grants.
Richard Pestell has remained committed to philanthropy, community service, and cultural engagement. At Georgetown and Jefferson, he led philanthropic efforts that produced transformational gifts and developed fundraising support for cancer care, wellness centers, and community outreach initiatives. He has served on boards including the National Museum of American Jewish History, the Chamber Orchestra of Philadelphia, the Jewish Federation of Greater Philadelphia, the Historic St. Peter’s Church Preservation Corporation, the American Cancer Society committees, and several university societies. He also supported the Olivia Newton-John Wellness Center through a fundraising trek on The Great Wall. He now serves as President of the Pennsylvania Cancer and Regenerative Medicine Center, as the Blumberg Distinguished Professor of Translational Medical Research at the Baruch Blumberg Institute, and as a member of the Wistar Institute Cancer Center, while continuing to mentor scientific leaders and develop technologies for improved diagnostics and treatment.
